
Eli Lilly (LLY) Drops After Company Misses Estimates, But the Future is Still Bright
Eli Lilly (LLY) stock has weakened lately, but the company is set toprofit handomely in the upcoming years from Mounjaro & Zepbound.
Eli Lilly (LLY) stock has weakened lately, but the company is set toprofit handomely in the upcoming years from Mounjaro & Zepbound.
Eli Lilly (LLY) has ramped up production of its Mounjaro diabetes drug, Zepbound weight loss drug, and Kisunla its Alzheimer’s drug.
Eli Lilly (LLY) has two blockbuster drugs Mounjaro and Zepbound boosting sales. Meanwhile, the company couldn’t make enough .
Eli Lilly (LLY) can’t keep up with demand for Mounjaro, and now it has to make Zepbound too. That’s good news for shareholders.
Eli Lilly (LLY) could be a leading stock for 2024 as its diabetes drug Mounjaro and its weight loss drug Zepbound are now available.
Eli Lilly (LLY) stock jumped following earnings which saw its diabetes drug Monjaro sales soar and news it could reduce heart risk.
Eli Lilly (LLY) shares have been soaring as Mounjaro for weight loss and Donanemab for Alzeimer’s could fuel profits for years.
Eli Lilly (LLY) capped the price of insulin it provides to Americans at $35 a month. But LLY’s weight loss drug should be the big news.
Eli Lilly (LLY) continues to rise as it has developed what could become the next big weight loss drug, pending approval from the FDA.
Eli Lilly (LLY) has two potential blockbuster drugs — for weight loss and Alzheimer’s — that could bring big profits down the road.